Celmatix

The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.

The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.

The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.

The award is one of 121 for projects in New York City this year, totaling $64.8 million.

The firm has secured NYS approval for its sequencing-based 32-gene Fertilome assay, which it originally launched in January. 

The companies will recruit and track a cohort of women to study environmental, genetic, and lifestyle factors that may contribute to fertility outcomes.

Fertility Genetics

Celmatix's Fertilome test aims to give women genetic insight into their fertility.

The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.

They will work to accelerate the launch of Celmatix's infertility genetics tests and develop early screening tests for declining ovarian function.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.